DA Davidson Raises Waldencast (NASDAQ:WALD) Price Target to $7.25

Waldencast (NASDAQ:WALD) had its price target increased by DA Davidson from $6.50 to $7.25 in a report published on Wednesday morning, Benzinga reports. DA Davidson currently has a buy rating on the stock.

Separately, Telsey Advisory Group decreased their target price on shares of Waldencast from $8.00 to $6.00 and set an outperform rating for the company in a research note on Thursday, August 29th.

Waldencast Stock Down 3.8 %

Shares of WALD opened at $3.52 on Wednesday. Waldencast has a twelve month low of $2.40 and a twelve month high of $12.00. The company has a 50 day moving average of $3.16 and a 200-day moving average of $4.66. The company has a quick ratio of 0.82, a current ratio of 1.47 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Waldencast

Several hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new stake in Waldencast during the 2nd quarter valued at $37,000. Catalina Capital Group LLC acquired a new stake in Waldencast during the 1st quarter valued at $73,000. Norden Group LLC acquired a new stake in Waldencast during the 1st quarter valued at $92,000. Bleakley Financial Group LLC acquired a new stake in Waldencast during the 1st quarter valued at $142,000. Finally, Simplicity Wealth LLC acquired a new stake in Waldencast during the 1st quarter valued at $142,000. Institutional investors and hedge funds own 41.97% of the company’s stock.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.